gliosarcoma, and giant cell GBM, and adds 2 unusual histological patterns: the GBM with oligodendroglial component and the small cell GBM. 13 The prognostic significance of these GBM subtypes remains controversial. 13 In addition, a handful of molecular parameters are clinically relevant. 27 In the context of large-scale prospective analyses, only O-6-methylguanine-DNA methyltransferase (MGMT) gene promoter methylation status has been validated as a predictor of prolonged PFS and overall survival in patients receiving TMZ. 6, 7, 21, 27 Recently, the IDH1 gene mutation has been identified in approximately 12% of all GBMs, serves as a diagnostic marker for secondary GBM, and is associated with a favorable prognosis for GBMs. 5, 14, 22, 28 Several gene expression studies confirm that GBMs are genetically heterogeneous. 4, 11, 18, 20, 26 A recent gene expression-based molecular classification distinguished 4 subgroups with different prognoses, and a "neural" GBM subgroup has been identified. 26 Interestingly, we have previously described a clinicopathological entity characterized by a mixed glial and neuronal immunophenotype without any neuronal or mature ganglion-like cells, which is associated with a better prognosis than classic GBM. 25 These malignant gliomas do not contain mature neurons, but instead demonstrate evidence of aborted neuronal differentiation, as defined by malignant tumor cells expressing NFP.
In this study, we attempted to better characterize neuronal immunoexpression markers in primary GBMs and define their associated clinical profile, including prognostic significance. In particular, we address the question of whether NFP can be reliably used as an independent predictor of overall survival in a large adult patient population with newly diagnosed supratentorial primary GBM that underwent treatment.
Methods

Patients and Tumor Samples
We identified 308 consecutive adult patients with newly diagnosed primary supratentorial GBM at the Paris-Descartes University Sainte-Anne Hospital Center, Paris, France, between January 2000 and August 2008. All secondary GBMs 19 and all pleomorphic xanthoastrocytomas with anaplastic features were excluded.
Detailed data regarding clinical presentation, imaging features, surgical procedure, pathological analysis, oncological treatment, PFS, and overall survival outcomes were recorded. The revised RTOG-RPA classification system for GBM was used for comprehensive clinical risk stratification. 15, 29 Although the RTOG-RPA classification was retrospectively assigned while blinded to patient survival, the data used to determine the RTOG-RPA classes were determined at the time of histological diagnosis. The extent of resection was determined by early postoperative images (within 48 hours). Gross-total resection of the contrast-enhanced area was determined only on MRI. The spatial relationship of the contrast-enhanced area with respect to the cortex and subventricular zone was determined on preoperative MRI according to a previously described classification method. 12 The institutional review board approved the study and all enrolled patients provided informed consent.
Pathological Analysis
All tumors were classified as GBM (WHO Grade IV astrocytoma). 13 Essential characteristics of the GBMs, including the presence or absence of necrosis, perinecrotic pseudopalisading cells, microvascular proliferation, giant cells, oligodendroglia-like, sarcomatous, primitive neuroectodermal-like, small cells, neuronal or other cellular components, and Ki 67 proliferation index were scored. A blind histopathological review was conducted (P.V.). Six patients (1.9%) were excluded after histopathological review due to the lack of a predominant malignant astrocytic component (n = 3) and due to the focal presence of a ganglion-like cell component (n = 3). In addition, 13 GBM variants (4.2%) were changed. All GBMs with an oligodendroglial component were carefully examined to rule out reactive astrocytes and to ensure a negative IDH1 immunoexpression. All gliosarcoma and giant cell GBMs were carefully examined to confirm the negative reticulin immunoexpression.
Immunohistochemical Analysis
Immunostaining was performed at the time of initial diagnostic workup as a part of routine tumor tissue characterization. Representative zinc formalin-fixed sections (formalin 5%, zinc 3 g/L, sodium chloride 8 g/L) were deparaffinized and subjected to a Ventana autostainer (BenchMark XT, Ventana Medical Systems) using a standard pretreatment protocol, including CC1 buffer for chromogranin, GFAP, and MIB, or to a Ventana autostainer (Discovery XT, Ventana Medical Systems) for NFP using a pretreatment protocol that included CC2 buffer. A semi-automatized system was employed using microwave antigen retrieval (MicroMED T/T Mega; Hacker Instruments & Industries, Inc.) for 30 minutes at 98°C (manufacturer recommendations). Sections were then incubated with various commercial monoclonal primary antibodies against GFAP (clone 6F2, 1:200 dilution; Dako); NFP clone 2F11, which reacts with the phosphorylated forms of the 70-kilodalton component of this protein (1:25; Dako); and MIB-1 (1:100; Dako). Diaminobenzidine was used as the chromogen. A minimal threshold at 1% of the total stained tumor cells served as a cutoff for defining NFP-positive status. A careful analysis of all parts of the tumor tissue section, including the leptomeningeal infiltrative areas, was performed to ensure the absence of a false-positive interpretation of normal entrapped neurons. Mitotic, NFP-positive cells were scored. An MIB-1 labeling index was obtained by counting the number of MIB-1-positive tumor cells in regions with the maximum number of labeled tumor cells. Ten microscopic hpf sets were counted, and the MIB-1 labeling index was computed as a percentage of immunopositive cells from the total cells counted in selected fields. Light microscopic images were digitally captured using a Nikon eclipse E600 microscope equipped with a Nikon DXM 1200 digital camera. Photomicrographs were assembled for illustrations using Adobe Photoshop software (version 7.0.1, Adobe).
Statistical Analysis
Data for age, sex, KPS score, imaging findings (tumor midline crossing on FLAIR sequences, cortical involvement and ventricular contact of the contrast-enhanced area), pathological diagnosis, type of surgery, oncological treatments, and RTOG-RPA classes were obtained as baseline variables. Descriptive results are presented as means ± SDs for continuous data and percentages for categorical data. Unpaired t-tests and the chi-square and Fisher exact tests were used, when appropriate, to compare patient demographic and clinical characteristics, tumor characteristics, prognostic factors, and treatment type according to NFP status. Kaplan-Meier analysis was used for unadjusted survival curves, using log-rank tests to assess significance. The primary end point was overall survival, measured from the date of histological diagnosis to the date of death. This interval was censored from the date of last follow-up for survivors. The secondary end point was PFS, which was measured from the date of histological diagnosis to the date of first radiological evidence of progression, or to the date of death. This interval was censored at the date of last follow-up for survivors. Cox proportional hazards models were constructed, adjusting for predictors previously associated with death in univariate analysis. Two-way interaction terms were tested, assessing whether the effect of NFP status on overall survival or PFS was modified by age, sex, or treatment type. The proportional hazards assumption was tested with Schoenfeld residuals and was found to remain true. A 2-tailed probability value < 0.05 was considered statistically significant. All statistical analyses were performed using Stata software (version 10.0, StataCorp).
Results
Pathological Analysis
The study population consisted of a total of 302 patients harboring GBMs. In 177 cases (58.6%), NFP-positive cells were identified (NFP-positive GBM; Table 1 ). The NFP-positive tumor cells were cytologically indistinct from other tumor cells, and randomly distributed throughout the tumors (Fig. 1) . The number of NFPpositive tumor cells was highly variable from one tumor to another, with large areas often devoid of NFP-positive tumor cells. Mitotically active NFP-positive tumor cells, ranging from rare to numerous, were present in 117 NFPpositive GBMs (66.1%). There was a difference in the distribution of GBM subtypes between NFP-positive GBMs and NFP-negative GBMs, with more GBMs with an oligodendroglial component (22/33), more giant cell GBMs (14/14) , and more gliosarcomas (2/2) in the NFP-positive GBM group (p = 0.0005; Table 1 ). An obvious leptomeningeal extension was more likely to be observed in NFPpositive GBMs (34 cases, 19.2%) than in NFP-negative GBMs (8 cases, 6.4%; p = 0.04).
Clinical Parameters
Patients with NFP-positive GBMs (57.0%) were significantly younger in age < 60 years old) at histological diagnosis than those with NFP-negative GBMs (36.8%; p < 0.0001). There were no significant differences in sex distribution, KPS score at histological diagnosis, or time to diagnosis (interval between first symptom and histological diagnosis, median 1 month, mean 1.5 ± 1.7 months) between the NFP-positive and NFP-negative GBM groups.
Morphological Parameters
There was significantly more temporal lobe tumor localization (p = 0.029) and more cortical involvement by the contrast-enhanced area of the tumor (p = 0.0003; Fig.  1 ) in NFP-positive GBMs. There was significantly more ventricular contact of the contrast-enhanced area of the tumor (p < 0.0001) and more tumor midline crossing on FLAIR sequences (p = 0.03) in NFP-negative GBMs.
Oncological Treatments
There was a significantly greater extent of resection, particularly with respect to gross-total resection, among NFP-positive GBMs (p < 0.0001). Oncological treatment modalities significantly differed between NFP-positive and NFP-negative GBMs (p < 0.0001). Specifically, there was significantly more radiotherapy combined with chemotherapy for NFP-positive GBMs, and more therapeutic abstention (biopsy only) for NFP-negative GBMs. The distribution of the RTOG-RPA classes varied significantly between groups (p < 0.0001), as there were more RPA Class IIIs among the NFP-positive GBMs and more RPA Classes V and VI among NFP-negative GBMs, consistent with the younger age and the higher rate of resection noted in NFP-positive GBMs.
Survival Analyses
The median duration of follow-up after histological diagnosis was 8.5 months (mean 11.0 months, range 0-64.8 months). Thirty-six patients (11.9%) were lost to follow-up at a median of 2.5 months (mean 2.3 months, range 0.5-6.5 months) following treatment. Of the remaining 266 patients with follow-up, 223 died (83.8%), 16 due to an unrelated cause (6.0%). Two hundred and two (75.9%) patients presented with radiographic evidence of tumor progression, which was subsequently confirmed histologically in 22 cases (10.9%) following a second resection.
The median overall survival was 11.0 months and the median PFS was 6.9 months after histological diagnosis. Kaplan-Meier estimates for overall survival and PFS by NFP status and oncological treatment are shown in Fig. 2 . The prognostic relevance of age, KPS score, tumor midline crossing on FLAIR sequences, NFP status, extent of resection, and oncological treatments are summarized in Table 2 . The median overall survival after histological diagnosis was significantly higher in patients with NFP-positive GBMs (13.0 months) than in those with NFP-negative GBMs (7.0 months). The 2-year overall survival rate was 23.6% for NFP-positive GBMs and 5.6% for NFP-negative GBMs. The 3-year overall survival rate was 15.0% for NFP-positive GBMs and 1.4% for NFP-negative GBMs. The 5-year overall survival rate was 2.7% for NFP-positive GBMs. The median PFS after histological diagnosis was significantly higher for NFP-positive GBMs (7.6 months) than for NFP-negative GBMs (5.1 months). No significant interaction was found between NFP status and sex, age, KPS score, extent of resection, and oncological treatments, either in overall survival or PFS analyses. A significant effect of the RTOG-RPA classes on overall survival and PFS only became apparent when patients with RTOG-RPA Classes V and VI were compared with patients with RTOG-RPA Class III.
We established multivariate survival models for overall survival and PFS, including the prognostic factors age at diagnosis, KPS score, tumor midline crossing, NFP status, extent of resection (complete resection), and oncological treatments (therapeutic abstention, radiotherapy combined with TMZ). These analyses were restricted to the patient population with full information on clinical parameters. Independent prognostic factors for overall survival were tumor midline crossing, NFP status, extent of resection, and type of oncological treatments. Independent prognostic factors for PFS were tumor midline crossing, NFP status, and type of treatments. Hazard ratios and CIs are summarized in Table 3 .
Discussion
Prognostic Significance of NFP Status for GBM
In this study we have shown that NFP-positive im- munoexpression, reflecting neuronal differentiation, represents a novel, strong, therapeutically independent prognostic factor for primary supratentorial GBM clinical outcome among adult patients. Specifically, we found that NFP-positive GBMs are less clinically aggressive than NFP-negative GBMs and are associated with better overall survival and PFS. The prognostic significance of NFPpositive immunoexpression persists in the subgroup of patients treated with radiotherapy combined with chemotherapy (TMZ). The expression of NFP is independently associated with prolonged overall survival and PFS in a Cox multivariable analysis. Consistent with most other large, population-based studies of GBMs, we confirmed that age, KPS score, and tumor volume-mass effect are primary prognostic factors for GBM. 5, 13, 23, 27 The grosstotal resection and the radiotherapy combined with chemotherapy (TMZ) associations are of prognostic value for both overall survival and PFS. The collected survival data are consistent with previously published ranges for GBM patients treated in France before and during the TMZ era. These results indicate that our study sample was from a homogeneous population of primary supratentorial GBMs without obvious selection bias in a consecutive series of adult patients.
Histopathological, Clinical, and Radiological Findings in the NFP-Positive GBM Subgroup
Distinctions among clinical, radiological, and pathological variables specific to NFP-positive and NFPnegative GBMs may be instructive in guiding clinical practice. Patients with NFP-positive GBMs present at a younger age, and these GBM types show a predilection for temporal lobe location, and are largely superficial in their distribution. In contrast, NFP-negative GBMs are deep-seated tumors that frequently contact the ventricle and are prone to develop bilaterality. These anatomical differences explain the higher rate of resection and the higher rate of RTOG-RPA subclasses III and IV among the NFP-positive GBMs, and the higher rate of RTOG-RPA Classes V and VI among NFP-negative GBMs. Interestingly, we find significantly more GBMs with an oligodendroglial component, gliosarcomas, and giant cell GBMs among NFP-positive GBMs, and a predominant pleomorphic cell GBM population in NFP-negative GBMs. This distinct distribution of histological variants suggests that NFP status may differentiate classic GBMs (NFP-negative) from variant GBMs (NFP-positive). Among younger patients, better outcomes for NFP-positive GBMs were observed and were consistent with longterm survival rates reported for patients with gliosarcoma and giant cell GBMs. 10 The preferential temporal location and the higher rate of resection of NFP-positive GBMs has been previously described for gliosarcomas, although their prognoses do not differ significantly from those of classic GBMs. 5, 9 Correlations between clinicopathological characteristics and MRI findings may provide additional insight into the cell type that is at the origin of the tumor. We observed distinct spatial patterns with respect to NFP status: the NFP-positive GBMs had more cortical involvement and less ventricular contact than NFP-negative GBMs. These divergent locations could suggest distinct sources of cellular origin for NFP-positive and NFP-negative GBMs, as previously proposed. 8, 12, 16 The NFP-negative GBMs have a predominant ventricular contact, in agreement with a reportedly shorter survival for patients with GBMs contacting the subventricular zone.
8,29
From a Clinicopathological Entity Toward a Neural Molecular GBM Subgroup
The heterogeneity of GBMs implies a need to establish coherent, integrated GBM subgroups. The NFP-positive GBM may be incorporated into a large CNS tumor subgroup previously described under the generic name of malignant glioneuronal tumors. 25 These tumors affect relatively young patients and are rather circumscribed, two characteristics that have been found to be associated with the neural GBM subgroup identified in a recent gene expression-based molecular classification. 25, 26 Their mixed immunophenotype suggests that malignant glioneuronal tumors may arise from the transformation of neural stem or progenitor cells. 25 Furthermore, the associated longterm renewal has not been observed in classic GBM, medulloblastoma, or ganglioglioma. 16 Of note, the malignant glioneuronal tumor entity may be distinguished from rare aggressive variants of glioneuronal tumors such as glioneuronal tumors with neuropil islands, 19, 24 anaplastic ganglioglioma, 13 GBM-primitive neuroectodermal tumor, 17 and pure oligodendroglioma with neuronal differentiation. 2 The neural GBM subgroup presents better patient survival than the classic GBM subgroup, in accordance with the present data. 26 Conversely, an archival study of selected cases, comprising a high proportion of gliosarcoma and giant cell GBMs, suggested that an isolated NFP-positive expression was associated with better survival, but failed to demonstrate the prognostic value of global neuronal differentiation. 3 Importantly, however, these data preceded the TMZ era. Whether NFP-positive GBMs are encompassed in the neural GBM subgroup remains unclear. Translational studies are thus necessary to assess the molecular subclassifications in terms of histological, molecular, NFP status, clinical, and radiological GBM characteristics.
Conclusions
In this study we demonstrate that NFP immunoexpression is a strong, therapeutically independent prognostic factor for primary supratentorial GBMs in adults. Thus, in addition to an IDH1 mutation, the NFP immunoexpression may help identify a distinct subgroup of primary GBMs with a favorable prognosis. The unique pathological features of these GBMs are associated with not only distinct clinical and anatomical behavior, but are also predictive of overall survival and PFS. Our findings emphasize the importance of diversity among GBMs, which should be considered in the design of future targeted therapies. 
